Credit: Pormezz/Shutterstock. China’s National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application (NDA) for Stapokibart to treat seasonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback